The first COVID-19 vaccine to reach phase 1 clinical trial has been found to be safe, well-tolerated, and able to generate an immune response against SARS-CoV-2 in humans, according to new research published in The Lancet.
A clinical trial in people with the new coronavirus is testing a drug that may halt an overactive immune response before it ramps up.
Tip sheet with latest Johns Hopkins research news NOT related to COVID-19. Stories: more women & seniors needed in cholesterol drug trials, improving medical care quality for homebound seniors & 2020 JHM Science Writers Boot Camp goes virtual.
In response to the COVID-19 pandemic, researchers from the Massachusetts Institute of Technology have published a pair of studies in a COVID-19 special issue of the Harvard Data Science Review, freely available via open access, describing new methods for accelerating drug approvals during pandemics and for providing more accurate measures of the probabilities of success for clinical trials of vaccines and other anti-infective therapies.
Researchers in the Ludwig Center at the Johns Hopkins Kimmel Cancer Center report they have identified a drug treatment that could—if given early enough—potentially reduce the risk of death from the most serious complication of Coronavirus disease 2019 (COVID-19), also known as SARS-CoV-2 i
Researchers at the University of Nebraska Medical Center have identified a key cell signaling pathway that drives the devastating muscle loss, or cachexia, suffered by many cancer patients. The study, which will be published May 22 in the Journal of Experimental Medicine, suggests that targeting this pathway with a drug already in phase 2 clinical trials for diabetes could prevent this syndrome.
A new paper published online in the Annals of the American Thoracic Society describes a nimble, pragmatic and rigorous multicenter clinical trial design to meet urgent community needs in the face of the COVID-19 pandemic.
MD Anderson and Innovent Biologics have announced a strategic collaboration agreement to co-develop Innovent's anti-PD-1 monoclonal antibody for treating rare cancers in the U.S.
MTX110 is a new formulation of panobinostat, a chemotherapy drug that has shown promise in laboratory models of medulloblastoma, the most common malignant brain tumor in children. Now, MTX110 is the focus of a novel trial that places the therapy directly into the fourth ventricle of the brain to treat patients with recurrent medulloblastoma.
Scientists at Sanford Burnham Prebys have discovered that combining immunotherapy with a drug called tumor necrosis factor (TNF) eradicated a deadly type of pediatric brain tumor in mice. The discovery, published in Nature Neuroscience, is expected to lead to a clinical trial to test the benefits of the treatment in patients. The findings also hold implications for other cancers that do not respond to immunotherapy.
New study reveals impact of COVID-19 pandemic on cancer clinical trials, published in Nature Reviews Drug Discovery
Researchers at the Washington University School of Medicine in St. Louis are helming a global study of an estimated 30,000 health-care workers to establish whether the antimalaria drug chloroquine might prevent or reduce the severity of COVID-19 infections in such workers.
Lowering testosterone may prevent the new coronavirus from entering lung cells and lessen COVID-19 severity, new Columbia University research suggests. A trial has now begun in three VA hospitals.
UCLA researchers have launched a new clinical trial that uses a hormone suppresser commonly used to treat men with prostate cancer to help improve clinical outcomes for men infected with COVID-19.
Treatment with antivirals such as interferons may significantly improve virus clearance and reduce levels of inflammatory proteins in COVID-19 patients, according to a new study in Frontiers in Immunology.
The NIH has launched a major clinical trial to assess the malaria drug hydroxychloroquine and antibiotic azithromycin as a treatment for COVID-19. The trial will recruit 2,000 participants at 30 sites. A Q&A with the trial’s team leader: Davey Smith, MD, of UC San Diego School of Medicine.
For the past 70 years, the best indicator of life expectancy for a patient with glioblastoma — the most common and the most aggressive brain cancer — has simply been age at diagnosis. Now, an international team of scientists has experimentally validated a predictor that is not only more accurate but also more clinically relevant: a pattern of co-occurring changes in DNA abundance levels, or copy numbers, at hundreds of thousands of sites across the whole tumor genome.
Drug trials and the latest on remdesivir and hydroxychloroquine studies, reports of possible vaccine progress, treating COVID in the ICU, public health policy and research on how the pandemic is progressing, can we safely “re-open,” what interventions have worked, which have not, and what still needs to be done.
A clinical trial led by Mount Sinai researchers has showed for the first time that combining chemotherapy and immunotherapy can slow down metastatic bladder cancer. The trial also showed that immunotherapy alone may be an option for a subset of patients with metastatic bladder cancer if their tumor expresses a high level of a protein called PD-L1 according to the study, published in The Lancet in May.
Research and experts on the symptoms and spread of COVID-19, impact on global trade and financial markets, public health response, search for an effective treatment, and more
The AIDS Clinical Trials Group (ACTG) has initiated a clinical trial to evaluate whether the drug combination hydroxychloroquine and azithromycin can prevent hospitalization and death from COVID-19.
A small study in Greece found that the clinically approved anti-inflammatory drug anakinra, used to treat rheumatoid arthritis, improved respiratory function in patients with severe coronavirus disease 2019 (COVID-19).
Moffitt Cancer Center organized a consortium of 16 cancer treatment facilities across the U.S. that offer Yescarta as a standard-of-care therapy for patients with relapsed/refractory large B cell lymphoma. They wanted to determine if the safety and effectiveness seen in the ZUMA-1 clinical trial were similar for patients treated with the now commercially available CAR T therapy. Their findings were published in the Journal of Clinical Oncology.
For the first time in over a decade, scientists have identified a first-line treatment that significantly improves survival for people with hepatocellular carcinoma, the most common type of liver cancer.
Orange, Calif., May 13, 2020 — UCI Health will initiate a clinical study of a drug to treat critically ill COVID-19 patients who face a high mortality rate because of acute inflammation that fills their lungs with fluid, a grave condition that even mechanical ventilation cannot improve. Aviptadil, which has a 20-year history of use in human clinical trials for lung ailments, will be employed in a phase 2b/3 clinical study of COVID-19 patients suffering from acute respiratory distress syndrome, a primary cause of coronavirus-induced death, said Dr.
A research collaboration and ensuing friendship between a trauma surgeon in Oregon and a handful of engineers in Florida has resulted in a new ventilator design that requires no electricity and could be a game-changer during the COVID-19 pandemic.
A two-drug immunotherapy combination first proposed by a Roswell Park team as an approach for treating cancer will soon be available to cancer patients with COVID-19 through a clinical trial at the Buffalo, N.Y., cancer center.
Scientists at Sanford Burnham Prebys Medical Discovery Institute and Loma Linda University Health have demonstrated the promise of applying magnetic resonance imaging (MRI) to predict the efficacy of using human neural stem cells to treat a brain injury—a first-ever “biomarker” for regenerative medicine that could help personalize stem cell treatments for neurological disorders and improve efficacy. The study was published in Cell Reports.
A monthly roundup of research briefs showcasing recent scientific advances led by Beth Israel Deaconess Medical Center faculty.
Clinical leaders from the University of Kentucky’s Markey Cancer Center, College of Medicine and College of Pharmacy have launched a clinical trial for experimental therapies to treat patients infected with COVID-19.
Memorial Sloan Kettering Cancer Center (MSK) announces the following awards and appointments.
The University of Kansas Cancer Center is helping fight the pandemic in numerous ways.
As the COVID-19 pandemic enters its third month, businesses in the United States are marketing unlicensed and unproven stem-cell-based "therapies" and exosome products that claim to prevent or treat the disease. In Cell Stem Cell on May 5, bioethicist Leigh Turner describes how these companies are "seizing the pandemic as an opportunity to profit from hope and desperation."
Olanzapine, a generic drug used to treat nervous, emotional and mental conditions, also may help patients with advanced cancer successfully manage nausea and vomiting unrelated to chemotherapy. These are the findings of a study published Thursday, May 7 in JAMA Oncology.
Evelo Biosciences, Inc. (Nasdaq:EVLO), Rutgers University, and Robert Wood Johnson University Hospital today announced the submission of an Investigational New Drug (IND) application for an Evelo-sponsored Phase 2 clinical study evaluating the safety and efficacy of EDP1815 for the treatment of hospitalized patients with newly diagnosed COVID-19. The study will be led by Reynold A. Panettieri, Jr., M.D., Vice Chancellor for Translational Medicine and Science at Rutgers Biomedical and Health Sciences and Professor of Medicine at Rutgers Robert Wood Johnson Medical School.
New clinical trial opened at Jefferson for novel COVID-19 treatment in 10 days.
Researchers at Beaumont Health have begun enrolling patients in a new clinical study aimed at treating COVID-19 patients with two common drugs.
A study to help determine the rate of novel coronavirus infection in children and their family members in the United States has begun enrolling participants.
The Altman Clinical and Translational Research Institute at University of California San Diego has received a five-year, $54.7 million Clinical and Translational Science Award from the National Center for Advancing Translational Science (NCATS), part of the National Institutes of Health.
UC San Diego scientists have launched a clinical trial to investigate whether a drug approved for treating high blood pressure might also reduce the severity of COVID-19 infections, lowering rates for intensive care unit admissions, the use of mechanical ventilators and all-cause mortality.
Glasses to stop myopia or nearsightedness in children have been shown to work in a multi-site trial of 256 children and will go on sale later this year outside the United States.
Health care workers at the University of Illinois Hospital and Health Sciences System, or UI Health, are participating in a national registry of frontline workers during the COVID-19 pandemic. The HERO Registry seeks to engage health care workers, understand their experiences and track health outcomes — from COVID-19 infection to stress and burnout.
UC San Diego Health has launched a Phase III clinical trial to assess whether a medication used to treat rheumatoid might also have therapeutic value for patient with COVID-19 who have developed or are at high risk of developing serious lung damage from SARS-CoV-2 infections.
Research by University of Iowa virologist Wendy Maury, has helped facilitate the launch of a new clinical trial in the United Kingdom of a drug that might help treat patients with COVID-19.
Montefiore Health System, Albert Einstein College of Medicine and NYU Langone have launched a new clinical trial to study if convalescent plasma—taken from people who have recovered from COVID-19—is effective in treating the disease.
Researchers at Montefiore Health System and Albert Einstein College of Medicine have begun testing the drug hydroxychloroquine for the treatment of COVID-19, as part of a nationwide trial sponsored by the National Heart, Lung, and Blood Institute (NHLBI).
Necessity being the mother of invention, Houston Methodist clinicians, researchers and staff have collaborated on a number of clinical device and research innovations in response to COVID-19. Houston Methodist Academic Institute leadership has continually emphasized translational research in new technologies.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right